Revvity, Inc.RVTY
NYSE • Healthcare
$91.46
P/E
43.90
PEG
—
FCF Yield
—
Rev Growth YoY
+367.0% YoY
Gross Margin
5477.0%
Health Score
5/10
D/E Ratio
0.44
Confidence
LOW
Business Snapshot
Revvity, Inc. (RVTY) is a healthcare diagnostics and research company operating on the NYSE within the Medical Diagnostics & Research industry. The company provides analytical tools, detection technologies, and life science solutions to research, clinical, and industrial markets globally. Based on available pricing data and the absence of a reported market cap figure, precise cap-tier classification cannot be confirmed, though the price level and sector positioning suggest a mid-to-large cap profile.
Financial Health
Score: 5/10 Revvity's balance sheet shows a conservative debt profile, with a Debt/Equity ratio of 0.44x — well below levels that typically raise concern. The current ratio of 1.68x suggests adequate short-term liquidity, meaning the company can cover near-term obligations comfortably...
Risk Assessment
- VALUATION RISK: P/E of 43.9x is approximately 76% above the sector average of 25x, with no PEG ratio or DCF estimate available to validate the premium.
- EARNINGS DETERIORATION: Earnings growth of -553.0% YoY directly contradicts the 367.0% revenue surge, suggesting significant margin compression or large below-the-line charges.
- DATA QUALITY RISK: Gross margin of 5,477% and net margin of 845% are statistically implausible for a normal operating period, signalling a distorted comparative base that reduces confidence in all derived metrics.
- TECHNICAL WEAKNESS: A confirmed death cross (50-day MA crossing below 200-day MA) with MACD in bearish territory, and the current price sitting 22.7% below the 52-week high of $118.30, indicate deteriorating price momentum.
- CASH FLOW OPACITY: Free cash flow is unavailable and the Python DCF model flagged negative FCF, meaning the company's ability to self-fund operations and return capital cannot be assessed.
---...
**Score: 5/10** Revvity's balance sheet shows a conservative debt profile, with a Debt/Equity ratio of 0.44x — well below levels that typically raise concern. The current ratio of 1.68x suggests adequate short-term liquidity, meaning the company can cover near-term obligations comfortably. However, the absence of Free Cash Flow data is a meaningful gap that prevents a full assessment of cash generation quality, and the reported margin figures (gross margin of 5,477% and net margin of 845%) contain statistical anomalies likely reflecting one-time accounting items or a restructuring period, limiting their interpretive value. ---
- **VALUATION RISK:** P/E of 43.9x is approximately 76% above the sector average of 25x, with no PEG ratio or DCF estimate available to validate the premium. - **EARNINGS DETERIORATION:** Earnings growth of -553.0% YoY directly contradicts the 367.0% revenue surge, suggesting significant margin compression or large below-the-line charges. - **DATA QUALITY RISK:** Gross margin of 5,477% and net margin of 845% are statistically implausible for a normal operating period, signalling a distorted comparative base that reduces confidence in all derived metrics. - **TECHNICAL WEAKNESS:** A confirmed death cross (50-day MA crossing below 200-day MA) with MACD in bearish territory, and the current price sitting 22.7% below the 52-week high of $118.30, indicate deteriorating price momentum. - **CASH FLOW OPACITY:** Free cash flow is unavailable and the Python DCF model flagged negative FCF, meaning the company's ability to self-fund operations and return capital cannot be assessed. ---
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives